StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
63
This year
9
Publishing Date
2024 - 03 - 08
1
2024 - 03 - 07
1
2024 - 03 - 06
2
2024 - 03 - 04
2
2024 - 02 - 29
2
2024 - 01 - 03
1
2023 - 12 - 18
1
2023 - 11 - 13
1
2023 - 11 - 10
1
2023 - 11 - 08
1
2023 - 10 - 17
1
2023 - 10 - 10
1
2023 - 10 - 09
1
2023 - 10 - 04
1
2023 - 08 - 31
1
2023 - 08 - 28
1
2023 - 08 - 11
1
2023 - 06 - 23
1
2023 - 06 - 01
1
2023 - 05 - 31
1
2023 - 05 - 16
1
2023 - 05 - 15
1
2023 - 03 - 29
1
2023 - 03 - 17
1
2023 - 01 - 10
1
2023 - 01 - 04
1
2022 - 12 - 21
1
2022 - 11 - 10
1
2022 - 11 - 07
2
2022 - 11 - 04
1
2022 - 10 - 11
1
2022 - 09 - 19
1
2022 - 09 - 15
2
2022 - 09 - 13
1
2022 - 09 - 08
2
2022 - 08 - 04
1
2022 - 06 - 27
2
2022 - 06 - 16
1
2022 - 06 - 13
1
2022 - 06 - 01
1
2022 - 05 - 06
2
2022 - 05 - 02
1
2022 - 02 - 25
1
2022 - 02 - 08
1
2022 - 01 - 06
1
2022 - 01 - 04
1
2021 - 12 - 07
1
2021 - 11 - 26
1
2021 - 11 - 09
1
2021 - 08 - 04
1
2021 - 06 - 21
1
2021 - 05 - 28
1
2021 - 04 - 26
1
2020 - 11 - 12
1
2020 - 10 - 21
1
Sector
Finance
13
Health technology
63
Professional, scientific, and technical services
1
Tags
Biotech-bay
1
Biotech-beach
1
Business
4
Cirrhosis
2
Clinical-trials-phase-ii
3
Commercial
1
Conference
13
Correlation
1
Designation
4
Device
1
Diabetes
3
Disease
1
Drug
1
Earnings
2
Efruxifermin
26
Enroll
2
Ev
1
Events
1
Expansion
1
Expected
1
Fast track
1
Fast track designation
1
Fda
4
Fda fast track
1
Fda-approvals
2
Fibrosis
6
Financial
6
Financial results
6
First
1
Granted
2
Growth
1
Health
1
Hepatitis
1
International
3
J.p. morgan healthcare conference
2
Liver
18
Meeting
4
Money
3
N/a
86
Nash
27
Offering
9
People
3
Phase 2
7
Phase 2b
13
Positive
3
Presentation
5
Program
2
Publication
2
Report
3
Research
2
Results
24
Study
11
Therapeutics
63
Therapy
5
Today
2
Treatment
8
Trial
7
Update
6
Week
2
Year
2
Entities
Akero therapeutics, inc.
63
Amgen inc.
1
Canadian imperial bank of commerce
1
Fate therapeutics, inc.
2
Gilead sciences, inc.
1
Glaxosmithkline plc
1
Hercules capital, inc.
2
Hsbc holdings plc
1
Iveric bio, inc.
1
Legend biotech corporation
2
Morgan stanley
10
Pfizer, inc.
2
Sanofi
1
Xilio therapeutics inc
1
Symbols
ABBV
88
ABEO
73
ADCT
82
AGRX
61
AKBA
67
AKRO
63
ALDX
58
ALGS
57
ALLO
86
AMGN
69
AQST
82
ATHE
74
AXSM
79
AZN
70
AZNCF
65
BCLI
57
BTAI
62
CDTX
61
CGTX
79
CRSP
61
CTMX
64
FBIO
73
FNCTF
66
FOLD
56
FULC
74
GLAXF
74
GSK
83
GTHX
81
HOTH
68
HZNP
74
IKT
66
JNJ
186
JSPR
59
KYMR
64
LLY
139
MCRB
62
MS
148
NRIX
61
NTLA
56
NVS
114
NVSEF
109
ONCT
57
OTLK
71
PLRX
70
PSTV
84
PSTX
60
PTCT
57
RLFTF
80
RLFTY
80
RNAZ
68
SNY
342
SNYNF
320
SPRO
70
SRPT
72
SWTX
58
TCRX
65
TEVJF
64
TGTX
88
TVTX
79
VYGR
74
Exchanges
Nasdaq
63
Nyse
14
Crawled Date
2024 - 03 - 08
1
2024 - 03 - 07
1
2024 - 03 - 06
2
2024 - 03 - 04
2
2024 - 02 - 29
2
2024 - 01 - 03
1
2023 - 12 - 18
1
2023 - 11 - 13
1
2023 - 11 - 10
1
2023 - 11 - 08
1
2023 - 10 - 17
1
2023 - 10 - 10
1
2023 - 10 - 09
1
2023 - 10 - 04
1
2023 - 08 - 31
1
2023 - 08 - 28
1
2023 - 08 - 11
1
2023 - 06 - 23
1
2023 - 06 - 01
1
2023 - 05 - 31
1
2023 - 05 - 16
1
2023 - 05 - 15
1
2023 - 03 - 29
1
2023 - 03 - 17
1
2023 - 01 - 10
1
2023 - 01 - 04
1
2022 - 12 - 21
1
2022 - 11 - 10
1
2022 - 11 - 07
2
2022 - 11 - 04
1
2022 - 10 - 11
1
2022 - 09 - 19
1
2022 - 09 - 15
2
2022 - 09 - 13
1
2022 - 09 - 09
1
2022 - 09 - 08
1
2022 - 08 - 04
1
2022 - 06 - 27
2
2022 - 06 - 16
1
2022 - 06 - 13
1
2022 - 06 - 01
1
2022 - 05 - 07
1
2022 - 05 - 06
1
2022 - 05 - 02
1
2022 - 02 - 25
1
2022 - 02 - 08
1
2022 - 01 - 06
1
2022 - 01 - 05
1
2021 - 12 - 07
1
2021 - 11 - 26
1
2021 - 11 - 13
1
2021 - 08 - 04
1
2021 - 06 - 21
1
2021 - 05 - 28
1
2021 - 04 - 26
1
2021 - 02 - 24
2
Crawled Time
01:00
2
03:00
1
06:00
1
10:00
1
11:00
10
12:00
11
12:01
1
13:00
6
13:20
1
14:00
4
15:25
2
15:30
1
16:20
2
19:00
2
20:00
7
21:00
8
22:00
1
23:00
2
Source
ir.akerotx.com
25
www.biospace.com
12
www.globenewswire.com
26
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Therapeutics
symbols :
Akro
save search
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published:
2024-03-08
(Crawled : 21:00)
- globenewswire.com
MS
|
News
0 d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
|
Email alert
Add to watchlist
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
Email alert
Add to watchlist
offering
therapeutics
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
Published:
2024-03-07
(Crawled : 21:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-32.77%
|
O:
0.16%
H:
5.27%
C:
0.81%
publication
therapeutics
study
Akero Therapeutics Announces Pricing of Public Offering of Common Stock - March 06, 2024
Published:
2024-03-06
(Crawled : 12:00)
- biospace.com/
MS
|
News
0 d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
|
1.72%
|
O:
-2.65%
H:
1.36%
C:
-1.28%
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-31.98%
|
O:
2.23%
H:
3.85%
C:
-3.85%
offering
therapeutics
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
Published:
2024-03-06
(Crawled : 03:00)
- globenewswire.com
MS
|
News
0 d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
|
1.72%
|
O:
-2.65%
H:
1.36%
C:
-1.28%
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-31.98%
|
O:
2.23%
H:
3.85%
C:
-3.85%
offering
therapeutics
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Published:
2024-03-04
(Crawled : 21:00)
- globenewswire.com
MS
|
News
0 d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
|
0.69%
|
O:
-0.94%
H:
2.19%
C:
-0.07%
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-33.18%
|
O:
-1.03%
H:
1.95%
C:
-0.75%
offering
therapeutics
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Published:
2024-03-04
(Crawled : 11:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-25.35%
|
O:
27.68%
H:
4.2%
C:
-12.5%
week
therapeutics
study
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Published:
2024-02-29
(Crawled : 13:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-23.76%
|
O:
2.94%
H:
6.28%
C:
-3.71%
efruxifermin
topline
week
therapeutics
results
study
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published:
2024-02-29
(Crawled : 12:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-23.76%
|
O:
2.94%
H:
6.28%
C:
-3.71%
business
year
update
therapeutics
financial
results
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published:
2024-01-03
(Crawled : 13:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-11.58%
|
O:
-0.72%
H:
0.0%
C:
-4.72%
conference
therapeutics
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
Published:
2023-12-18
(Crawled : 12:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-9.38%
|
O:
-0.87%
H:
0.0%
C:
-3.17%
first
efruxifermin
program
therapeutics
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published:
2023-11-13
(Crawled : 12:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
46.61%
|
O:
-0.14%
H:
1.41%
C:
0.42%
business
update
therapeutics
financial
results
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
Published:
2023-11-10
(Crawled : 14:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
47.44%
|
O:
1.85%
H:
0.0%
C:
-1.26%
meeting
liver
therapeutics
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
Published:
2023-11-08
(Crawled : 12:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
33.33%
|
O:
-0.32%
H:
0.0%
C:
-2.96%
therapeutics
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
Published:
2023-10-17
(Crawled : 20:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
44.37%
|
O:
-0.21%
H:
0.77%
C:
-4.32%
conference
therapeutics
nash
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Published:
2023-10-10
(Crawled : 11:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-57.23%
|
O:
-59.06%
H:
0.0%
C:
-8.66%
liver
fibrosis
therapeutics
results
insulin
nash
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Published:
2023-10-09
(Crawled : 20:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-57.23%
|
O:
-59.06%
H:
0.0%
C:
-8.66%
cirrhosis
efruxifermin
therapeutics
results
nash
study
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
Published:
2023-10-04
(Crawled : 12:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-56.26%
|
O:
0.76%
H:
0.63%
C:
-3.72%
lancet
publication
trial
therapeutics
results
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
Published:
2023-08-31
(Crawled : 11:00)
- globenewswire.com
MS
|
News
0 d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
|
5.79%
|
O:
-0.29%
H:
0.0%
C:
0.0%
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-58.24%
|
O:
-0.16%
H:
0.75%
C:
0.0%
therapeutics
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
Published:
2023-08-28
(Crawled : 11:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-56.72%
|
O:
3.79%
H:
4.04%
C:
0.4%
report
therapeutics
results
study
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Published:
2023-08-11
(Crawled : 10:00)
- globenewswire.com
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
|
-52.89%
|
O:
4.63%
H:
5.1%
C:
3.12%
business
update
therapeutics
financial
results
← Previous
1
2
3
4
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
GBR
|
$1.42
31.48%
11.27%
990K
|
Energy Minerals
KUKE
|
$2.88
2.49%
7.64%
360K
|
MPLN
|
$0.6502
-11.74%
4.51%
2.2M
|
Finance
CXM
4
|
$11.34
-0.44%
4.27%
1.7M
|
Information
PVL
4
|
$1.47
-0.68%
4.08%
77K
|
Energy Minerals
RNR
4
|
$224.74
0.85%
3.52%
310K
|
Finance
PZG
|
$0.4431
0.48%
2.91%
150K
|
Non-Energy Minerals
LEV
|
$0.972
0.73%
2.88%
570K
|
Manufacturing
AJX
4
|
$3.47
2.06%
2.02%
110K
|
Finance
LPTV
4
|
$0.2941
4.55%
2.01%
340K
|
Administrative and Support and ...
Your saved searches
Save your searches and get alerts when important news are released.